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SUMMARY
Background
Standard curative schedules of radiotherapy to the breast deliver 25 doses (fractions) of 2.0Gy treating 5 times per week. The hypothesis under test is that fewer, larger fractions are as safe as, and more effective than, regimens based on 2.0Gy fractions. If confirmed, curative radiotherapy in early breast cancer could be greatly simplified for the benefit of patients and health services.
Aim
To test the effects of radiotherapy fractions >2.0Gy on local tumour control and dose-limiting normal tissues of the breast after tumour excision and radiotherapy for early breast cancer.
The primary endpoint of normal tissue effects has been published elsewhere 6 .
Methods
1410 women with T1-3 N0-1 M0 invasive breast cancer were randomised between 1986-98 to receive one of three radiotherapy regimens after local tumour excision of early stage breast cancer; 50Gy in 25 fractions versus two dose levels of a test schedule giving 39Gy or 42.9Gy in 13 fractions over 5 weeks. Fraction sizes were 2.0Gy, 3.0Gy and 3.3Gy, respectively. The primary endpoint was late change in breast appearance. Secondary endpoints included ipsilateral tumour relapse, which is now reported for the first time.
Results
After a median follow up of 9.7 years (IQR 7.8-11.8) in the survivors, the current estimate of 10-year risk of ipsilateral tumour relapse was 12.1% (95% CI 8.8-15.5%) after 50Gy in 25F
and demonstrated a clear dose-response in the test arms: 14.8% (95% CI 11.2-18.3%) and 9.6% (95% CI 6.7-12.6%) after 39Gy and 42.9Gy in 13 fractions, respectively. The sensitivity trial launched in January 1999, which was designed to have sufficient statistical power to assess tumour control as the primary endpoint 7 . A meta-analysis of the tumour control data from both trials will be performed when the START trial data mature. This manuscript reports on local tumour control in the first trial.
METHODS
Patients
Details of the patient characteristics have been previously described 6 . requiring radiotherapy were eligible for the trial provided they were under 75 years at presentation, and had had breast preserving surgery and complete macroscopic resection of invasive carcinoma.
Trial design, entry procedure and follow up
Patients were randomised to 3 alternative dose schedules delivered over 5 weeks at an allocation ratio of 1:1:1. The control arm of 50Gy in 25 fractions over 5 weeks was compared with 2 dose levels of a test schedule delivering 13 fractions over 5 weeks. Fraction sizes of 3.0 and 3.3Gy were selected corresponding to schedules iso-effective with 50Gy in 25 fractions assuming α/β values of 1.8Gy and 6.0Gy, respectively.
Randomisation was achieved by a telephone call to the Clinical Trials and Statistics Unit
(ICR-CTSU) at the Institute of Cancer Research, Sutton, after obtaining informed consent.
Patients were stratified by treatment centre and by whether microscopic foci of invasive or intraduct disease were present at or close (<3mm) to the nearest surgical margin. In patients with a complete microscopic resection, when the clinician felt it was appropriate and the patient consented, a sub-randomisation to tumour bed boost versus no boost was performed.
This sub-randomisation closed in July 1997, and thereafter, all patients were offered an elective boost. Patients were reviewed 3-monthly to 3 years, 6-monthly to 5 years and annually thereafter.
Radiotherapy
Radiotherapy technique has been previously described 6 In all patients allocated to receive a boost, this was delivered by electrons to the tumour bed to a dose of 14Gy to the 90% iso-dose (15.5Gy to 100%) in 7 daily fractions. The proportion of patients who received a boost was almost identical in the three arms; 74.0% for 50Gy, 74.7%
for 42.9Gy and 74.0% of the patients randomised to receive 39Gy.
Definition and assessment of endpoint
Local relapse was defined as any malignancy occurring in ipsilateral breast parenchyma or overlying skin.
Statistical methods
The original sample size was estimated on the basis of not increasing the incidence of moderate or severe late radiation effects on normal tissues above 10% (assuming <5% in the 50Gy control arm), which was the primary endpoint. Mid trial, it was decided to extend the trial to allow a reliable comparison of relapse rates. It was estimated that for 90% power and a 5% significance level, 2250 patients would be needed to detect a 5% absolute increase in the risk of relapse in either experimental arm compared to an expected 5-year local relapse rate of 10% in the control arm (50Gy). Accrual into this trial was terminated before the target was reached, as this local initiative was superseded by the START trial, the corresponding national trial, which has tumour control as its primary endpoint.
The time from randomisation to first relapse or date last seen was calculated. The probability of no local relapse was depicted over the follow up period on a Kaplan-Meier survival curve, and pairs of fractionation schedules compared using the Logrank test. Kaplan-Meier (KM)
estimates of the probability of no local relapse at 5 and 10 years were obtained, with 95%
confidence intervals (CI). Cox proportional hazards (PH) regression was used to estimate the hazard ratios (with 95% CI) for local relapse for each fractionation schedule. Since point estimates of differences in event rates can, by chance, be atypical of the overall pattern of differences, smoothed estimates of absolute differences in relapse rates at 5 and 10 years were obtained using the hazard ratios obtained from the Cox model and the KM estimate of local relapse in the control arm. In order to obtain direct estimates (with 95% CI) of the α/β ratios for local relapse, a Cox PH regression model was fitted including a term for total dose and another term for total dose multiplied by dose per fraction. Analysis included all randomised patients on an intention-to-treat basis.
RESULTS
Patients and follow up
A total of 1410 patients were recruited, as shown in Figure 1 . Median follow up in those still alive was 9.7 years with an inter-quartile range (IQR) of 7.8 to 11.8 years and a maximum of 18.4 years. Eighteen patients (1.3%) were lost to follow up (median follow up 4.9 years, IQR 2.5-8.3). The trial protocol was to discharge patients at 10 years: 172 (12.2% of the total)
were discharged at a median follow-up time of 12.8 years (IQR 10.1-14.9) and 36 (2.5% of the total) were discharged early at a median of 7.8 years (IQR 7.0-8.9). At the time of analysis, 838 patients (59.4%) were alive and without local relapse, 46 (3.3%) were alive with local relapse (but no distant relapse or contralateral breast cancer), 46 (3.3%) were alive with distant relapse (including 10 with local relapse and 5 with contralateral breast cancer), 35 (2.5%) were alive with a second primary cancer in the contralateral breast (including 3 with local relapse) and 445 (31.6%) had died (99 of the patients who died had a local relapse).
Local relapse
At the time of the analysis, there were 158 local relapses out of the 1410 patients randomised (11.2%). Local relapse rates were highest between years three and five and 67% of all events occurred within five years of follow-up. Table 1 and Figure 2 show the results of the survival analysis of local relapse, comparing the fractionation schedules. A significant dose-response relationship was demonstrated for local relapse: when the 42.9Gy and 39Gy arms were compared, the logrank test was statistically significant (χ2 = 4.9, degrees of freedom (df) = 1, p = 0.027).
In Figure 2 there was evidence of divergence in the relapse-free survival curves for the fractionation schedules after five years of follow-up, whereas this did not appear to be the case in the first five years. Splitting the follow-up at five years and fitting separate Cox PH regression models for the two time periods supported this observation, as the hazard ratios in the first five years were closer to 1, compared with larger relative effects from five years onwards. In the first five years, the hazard ratios (95% CI) compared with 50Gy were 0.90 (0.55-1.46) for 42.9Gy and 1.14 (0.72-1.79) for 39Gy. From five years onwards, the hazard ratios (95% CI) compared with 50Gy for 42.9Gy and 39Gy were 0.77 (0.36-1.69) and 1.81
(0.96-3.41), respectively. However, the test of the proportional hazards assumption was not statistically significant (p = 0.1), indicating that the apparent differences between the two time periods were not substantial.
Alpha-beta value, equivalent dose in 2.0Gy fractions and dose-response
From the Cox PH regression, the direct estimate of the α/β ratios for local relapse is 4.0Gy (95% CI 1.0-7.8). Applying this value to estimate the equivalent total doses in 2.0Gy fractions, 39Gy in 3.0Gy fractions is equivalent to 46Gy in 2.0Gy fractions, and 42.9Gy in 3.3Gy fractions over 5 weeks is iso-effective with 52Gy in 2.0Gy fractions. By interpolation, 50Gy in 25 fractions is iso-effective with 41.6Gy in 13 fractions of 3.2Gy over 5 weeks.
These iso-effect doses allow estimation of the local steepness of the dose-response curve, the normalised dose-response gradient (γ-value), corresponding to a 0.5% increase in local control probability for a 1% increase in total dose. Thus, a 2% absolute improvement in local control rate is the consequence of a 2Gy increment in total dose.
DISCUSSION
Based on an analysis of 158 ipsilateral local tumour relapse events, an estimated α⁄β value of 4.0Gy (95% CI 1.0-7.8) compares closely with 3.6Gy (95% CI 1.8-5.4) for any change in breast appearance, and with 3.1Gy (95% CI 1.8-4.4) for moderate/marked induration reported in the same trial 6 . This is to the best of our knowledge the first direct estimate of fractionation sensitivity of human breast cancer. An important observation from the present trial is the significant dose-response relationship for local tumour control. A γ-value around 0.5 may appear low, but in the adjuvant situation the dose-response curve does not range from 0% to 100% control, since 70% or so of the patients are locally controlled by surgery alone 8 The clinical implications for breast cancer patients and health services will be profound if it is reliably demonstrated that the fractionation sensitivity of breast cancer is comparable to that of the dose-limiting normal tissues of the breast, including underlying pectoral muscle and ribcage. Although the data do not apply to treatment of the lymphatic pathways, where the brachial plexus is known to be highly sensitive to fraction size, there would be no reason to prefer 2.0Gy fractions for the majority of women requiring radiotherapy to the conserved breast or post-mastectomy chest wall. The challenge will be to determine the useful limits of hypofractionation. Current initiatives in this area include the randomised UK FAST Trial, which compares two dose levels (5.7Gy and 6.0Gy) of a 5-fraction regimen over 5 weeks against 50Gy in 25 fractions delivered using 3D dose-compensated whole breast radiotherapy.
It should be stressed that although our trial results are consistent with the hypothesis under test, they are not sufficiently reliable on their own to justify hypofractionation outside the context of well designed randomised trials. 
